^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gastroesophageal Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Future Oncol
    Title:

    Real-world association of HER2/ ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer

    Published date:
    08/31/2021
    Excerpt:
    Clinical outcomes were assessed for patients with HER2+ advanced esophagogastric cancer who received first-line trastuzumab....Among patients who received first-line trastuzumab, concordant HER2/ERBB2 was associated with longer time to treatment discontinuation (adjusted hazard ratio [aHR]: 0.63; 95% CI: 0.43–0.90) and overall survival (aHR: 0.51; 95% CI: 0.33–0.79)….HER2/ERBB2 concordance and higher ERBB2 copy number predicted clinical benefit from trastuzumab.
    DOI:
    https://doi.org/10.2217/fon-2021-0203
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

    Excerpt:
    ...HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or FISH (≥2.0)...
    Trial ID:
    NCT02023996